OncoMatch/Clinical Trials/NCT03850366
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Is NCT03850366 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Bortezomib for hematological malignancy.
Treatment: Bortezomib — Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
KARNOFSKY 0–1
Lab requirements
Kidney function
Serum creatinine clearance >=60 ml/min (Cockroft-Gault formula)
Liver function
Bilirubin <= 1.5 mg/dl, AST or ALT <= 200 IU/ml for adults.
Cardiac function
Left ventricle ejection fraction > 40%
Bilirubin <= 1.5 mg/dl , aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <= 200 IU/ml for adults. Serum creatinine clearance >=60 ml/min (calculated with Cockroft-Gault formula). Left ventricle ejection fraction > 40%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Henry Ford hospital · Detroit, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify